INZY

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-655.5K ExitQ3 2025 $655k -- $4.00
Jim SimonsRenaissance Technologies $-1.9M ExitQ3 2025 $2M -- $4.00
Mario GabelliGAMCO Investors $-240.0K ExitQ3 2025 $240k -- $4.00
Ken GriffinCitadel Advisors $478.2K AddQ2 2025 $478k -- $4.00
Jim SimonsRenaissance Technologies $1.4M AddQ2 2025 $1M -- $4.00
Ken GriffinCitadel Advisors $-1.6M TrimQ1 2025 $2M -- $4.00

Insider Trades

Name	Value	Action	Price	Current Price
Treco Douglas ADirector, Officer: CEO & Chairman $7.8k8.8k shares SellApr 2, 2025 $0.89 $4.00

Trade INZY

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

CEO: Douglas A. Treco
IPO Date: Jul 24, 2020

Market Data

Open: $4.00
High: $4.00
Low: $4.00
Volume: 1.5M
52W High: $6.24
52W Low: $0.721

Valuation

Market Cap: $258.2M
Enterprise Value: $279.4M

Financials

Free Cash Flow: -$92M
Revenue: $0
Net Income: -$102M
Cash: $21.1M
Debt: $46.9M

Events

EarningsAug 5

EPS est. -0.36 · actual -0.44